APD 597

Drug Profile

APD 597

Alternative Names: APD597; JNJ-38431055

Latest Information Update: 18 Jul 2011

Price : $50

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2010 Safety and pharmacokinetics data from a phase I clinical programme released by Arena Pharmaceuticals
  • 09 Nov 2010 Ortho-McNeil-Janssen Pharmaceuticals announces termination of collaboration with Arena Pharmaceuticals
  • 19 Dec 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top